首页> 美国卫生研究院文献>Springer Open Choice >Investigation of novel circulating proteins germ line single-nucleotide polymorphisms and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

【2h】

Investigation of novel circulating proteins germ line single-nucleotide polymorphisms and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

机译：研究新型循环蛋白种系单核苷酸多态性和分子肿瘤标志物作为一线舒尼替尼治疗晚期肾细胞癌的潜在功效生物标志物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Sunitinib is a first-line advanced renal cell carcinoma (RCC) standard of care. In a randomized phase II trial comparing sunitinib treatment schedules, separate exploratory biomarker analyses investigated the correlations of efficacy with selected serum, germ line single-nucleotide polymorphism (SNP), or tumor markers.

机译：目的舒尼替尼是一线晚期肾细胞癌（RCC）护理标准。在一项比较舒尼替尼治疗方案的随机II期试验中，单独的探索性生物标志物分析研究了功效与所选血清，种系单核苷酸多态性（SNP）或肿瘤标志物之间的相关性。

著录项

期刊名称 Springer Open Choice
作者
Robert J. Motzer; Thomas E. Hutson; Gary R. Hudes; Robert A. Figlin; Jean-Francois Martini; Patricia A. English; Xin Huang; Olga Valota; J. Andrew Williams;
展开▼
作者单位

展开▼
年(卷),期 -1(74),4
年度 -1
页码 739–750
总页数 12
原文格式 PDF
正文语种
中图分类外科学;
关键词
Sunitinib Renal cell carcinoma Serum marker Germ line polymorphism marker Tumor marker;

机译：舒尼替尼;肾细胞癌;血清标志物;生殖系多态性标志物;肿瘤标志物;

相似文献

外文文献
中文文献
专利

1. Investigation of novel circulating proteins, germ.lineMngle-nii^leoticle.polymorphisms, and molecular tumor markers as- potential efficacy biomarkers of first-line sunitinib therapy for advanced renal-cell carcinoma [J] . Eobert J. Motzer, Thomas E. Hutson, Gary R. Hudes, Cancer chemotherapy and pharmacology. . 2014,第4期

机译：舒尼替尼一线治疗晚期肾细胞癌的新型循环蛋白，种系Mngle-nilelelelele，多态性和分子肿瘤标志物作为潜在疗效生物标志物的研究
2. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-na?ve patients with metastatic renal cell carcinoma [J] . HarmonC.S., DeprimoS.E., FiglinR.A., Cancer chemotherapy and pharmacology. . 2014,第1期

机译：循环蛋白作为舒尼替尼和干扰素-α在潜在的初治转移性肾细胞癌患者中的潜在生物标志物
3. Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy” [J] . Chiara Nicolazzo, Cristina Raimondi, Flavia Loreni, International Journal of Molecular Sciences . 2017,第6期

机译：致编辑的信：“循环无细胞DNA和循环肿瘤细胞是一线化疗治疗的晚期非小细胞肺癌患者的预后和预测生物标志物”
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Integrated Molecular Analysis for the Identification and Validation of Novel Biomarkers for Renal Cell Carcinoma and the Small Renal Mass [D] . Di Meo, Ashley . 2019

机译：肾细胞癌新生物标志物的鉴定和验证综合分子分析及小肾肿块
6. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma [O] . Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, -1

机译：循环蛋白在未治疗的转移性肾细胞癌患者中作为舒尼替尼和干扰素-α疗效的潜在生物标志物
7. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma [O] . Robert J. Motzer, Thomas E. Hutson, Gary R. Hudes, 2014

机译：研究新型循环蛋白，种系单核苷酸多态性和分子肿瘤标志物作为一线舒尼替尼治疗晚期肾细胞癌的潜在功效生物标志物

Investigation of novel circulating proteins germ line single-nucleotide polymorphisms and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅